Please login to the form below

Not currently logged in
Email:
Password:

Imnovid

This page shows the latest Imnovid news and features for those working in and with pharma, biotech and healthcare.

NICE U-turn sees Celgene's Imnovid backed for multiple myeloma

NICE U-turn sees Celgene's Imnovid backed for multiple myeloma

New data and a discount swayed the cost-effectiveness body. The National Institute for Health and Care Excellence has backed Celgene's multiple myeloma pill Imnovid (pomalidomide) in combination with dexamethasone ... Imnovid has been given the nod for

Latest news

  • Cancer Drugs Fund axes 16 treatments after overspending Cancer Drugs Fund axes 16 treatments after overspending

    Patients in Scotland will nevertheless still be able to receive both treatments and the All Wales Medicine Strategy Group (AWMSG) recently approved Imnovid for use on the NHS. ... Wim Souverjins, general manager at Celgene UK &Ireland, said: “We are

  • Final NICE ‘no’ for Celgene’s Imnovid Final NICE ‘no’ for Celgene’s Imnovid

    NICE has issued final draft guidance rejecting Celgene's next-generation multiple myeloma pill Imnovid (pomalidomide) on account of its high price. ... Imnovid is the next generation version of both Thalidimod and Revlimid and this appraisal considers

  • Celgene gets first-line myeloma approval for Revlimid Celgene gets first-line myeloma approval for Revlimid

    Celgene said recently that strong growth for Revlimid as well as its newer products, including Pomalyst/Imnovid (pomalidomide) for myeloma - which the company predicts will become a multibillion-dollar product - as

  • NICE issues fresh rejection for Celgene’s cancer drug Imnovid NICE issues fresh rejection for Celgene’s cancer drug Imnovid

    NICE has issued final draft guidance that rejects the use of Celgene's next generation multiple myeloma pill Imnovid (pomalidomide) because it is too expensive. . ... Imnovid is the next generation version of both Thalidimod and Revlimid and this

  • Cancer drugs lead SMC recommendations Cancer drugs lead SMC recommendations

    The SMC, which rules on what drugs are available for NHS reimbursement, backed Roche's Gazyvaro (obinutuzumab), Eli Lilly's Alimta (pemetrexed) and Celgene's Imnovid (pomalidomide), in addition to several ... The recommendation for Alimta is regarding

More from news
Approximately 6 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Skills in Healthcare

At Skills in Healthcare, we are able to provide our customers with a professional set of sales capabilities. With our...

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics